Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
The Mark Foundation for Cancer Research
BioCentury | Dec 19, 2024
Product Development
Tertiary lymphoid structures: Key to predicting and improving cancer immunotherapy response?
At least two companies are preparing to take inducers of tertiary lymphoid structure into the clinic
BioCentury | Jan 26, 2024
Finance
VC roundup: Synnovation chases familiar targets, Mirae’s new U.S. firm backs Accent
Plus deals for GenEdit, Elephas and more
BioCentury | Oct 10, 2023
Emerging Company Profile
Hyku: tapping new targets by taking chemoproteomics beyond cysteine
In co-leading Hyku’s $56M seed round, RA Capital added to its portfolio of chemoproteomics companies
BioCentury | Jul 28, 2022
Emerging Company Profile
Vicinitas: stabilizing proteins with small molecules
a16z, Deerfield co-lead $65M series A for UC Berkeley spinout’s small molecule deubiquitination platform
BioCentury | May 20, 2022
Management Tracks
Schoenfeld becomes Mark Foundation CEO
Plus new CDO at iosBio, and updates from Cerebral, Helsinn, CureDuchenne and more
BioCentury | Aug 18, 2021
Emerging Company Profile
Immunitas: Strategics back $58M B round to push CD161 inhibitor into the clinic
Emerging Company Profile: First-in-class immuno-oncology therapy from Boston single cell genomics play attracts 16 investors
BioCentury | Jun 4, 2021
Emerging Company Profile
Interius design: Penn spinout gets specific with in vivo CAR Ts
Emerging Company Profile: Philadelphia cell and gene therapy play has $76M from Cormorant, Fairmount to get to clinic
BioCentury | Apr 16, 2021
Politics, Policy & Law
Pandemic pain: how COVID-19 has devastated patient groups
Patient groups that are an essential part of the life sciences ecosystem are suffering from increased demands and decreased funding
BioCentury | Jun 12, 2020
Finance
June 11 Quick Takes: Biotech swept up in sell-off; plus Simcere, Lantern, Cue Health, C2i, BaseLaunch, Sanofi-Cathay and 4BIO
Items per page:
1 - 10 of 12